Generic drug
Leflunomide price, strengths & recalls
Pharmacies pay $9.30 for 30 tablets of Leflunomide 20 mg tablet this week, and from $9.30 to $10.01 across its 2 priced strengths and forms. 12 manufacturers make it. It is in shortage (being discontinued). It has 4 recalls on record, none ongoing. Its official label last changed on December 19, 2025.
Being discontinuedGeneric- Fair cash price
- $21.20
- Strengths
- 2
- Makers
- 12
- Updated
- Nov 11
Leflunomide price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 10 mg tablet | $0.3337 | $10.01 / 30 tablets |
| 20 mg tablet | $0.3100 | $9.30 / 30 tablets |
Supply status: shortages & recalls
Shortages
- Arava, Tablet, 10 mg (NDC 0088-2160-30)Discontinuation of the manufacture of the drug
- Leflunomide, Tablet, 10 mg (NDC 0955-1735-30)Discontinuation of the manufacture of the drug
- Arava, Tablet, 100 mg (NDC 0088-2162-33)Discontinuation of the manufacture of the drug
- Leflunomide, Tablet, 20 mg (NDC 0955-1737-30)Discontinuation of the manufacture of the drug
- Arava, Tablet, 20 mg (NDC 0088-2161-30)Discontinuation of the manufacture of the drug
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Leflunomide
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
Leflunomide Tablets, USP 10 mg and 20 mg These highlights do not include all the information needed to use LEFLUNOMIDE TABLETS safely and effectively. See full prescribing information for LEFLUNOMIDE TABLETS. LEFLUNOMIDE tablets, for oral use Initial U.S. Approval: 1998
WARNING: EMBRYO-FETAL TOXICITY and HEPATOTOXICITY
Embryo-Fetal Toxicity
Leflunomide is contraindicated for use in pregnant women because of the potential for fetal harm. Teratogenicity and embryo-lethality occurred in animals administered leflunomide at doses lower than the human exposure level. Exclude pregnancy before the start of treatment with leflunomide in females of reproductive potential. Advise females of reproductive potential to use effective contraception during leflunomide treatment and during an accelerated drug elimination procedure after leflunomide treatment. Stop leflunomide tablets and use an accelerated drug elimination procedure if the patient becomes pregnant.
[see
Contraindications (4), Warnings and Precautions (
5.1,
5.3), Use in Specific Populations (
8.1,
8.3), and
Clinical Pharmacology (12.3)]
Hepatotoxicity
Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide. Leflunomide is contraindicated in patients with severe hepatic impairment. Concomitant use of leflunomide with other potentially hepatotoxic drugs may increase the risk of liver injury. Patients with pre-existing acute or chronic liver disease, or those with serum alanine aminotransferase (ALT) >2xULN before initiating treatment, are at increased risk and should not be treated with leflunomide. Monitor ALT levels at least monthly for six months after starting leflunomide, and thereafter every 6 to 8 weeks. If leflunomide-induced liver injury is suspected, stop leflunomide treatment, start an accelerated drug elimination procedure, and monitor liver tests weekly until normalized.
[see
Contraindications (4), Warnings and Precautions (
5.2,
5.3),
Use in Special Populations (8.6)]
WARNING: EMBRYO-FETAL TOXICITY and HEPATOTOXICITY
See full prescribing information for complete boxed warning.
Embryo-Fetal Toxicity
Teratogenicity and embryo-lethality occurred in animals administered leflunomide. (
5.1,
8.1)
Exclude pregnancy prior to initiating leflunomide tablets therapy. (
5.1,
8.3)
Advise use of effective contraception in females of reproductive potential during treatment and during a drug elimination procedure. (
5.1,
5.3,
8.3)
Stop leflunomide tablets and use an accelerated drug elimination procedure if the patient becomes pregnant. (
5.1,
5.3,
8.1)
Hepatotoxicity
Severe liver injury and fatal liver failure have been reported. (
5.2)
Avoid leflunomide use in patients with pre-existing liver disease, or those with serum alanine aminotransferase (ALT)>2xULN. (
5.2,
8.6)
Use caution when leflunomide is given with other potentially hepatotoxic drugs. (
5.2)
Monitor ALT levels. Interrupt leflunomide treatment if ALT elevation > 3 fold ULN. If likely leflunomide-induced, start accelerated drug elimination procedure and monitor liver tests weekly until normalized. (
5.2,
5.3)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 7 approved generic applications on the market
Leflunomide questions
How much does leflunomide cost without insurance?
Pharmacies pay about $9.30 for 30 tablets of leflunomide 20 mg tablet ($0.3100 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $21.20. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is leflunomide in shortage?
Yes. 5 products are listed as in shortage or being discontinued (being discontinued). See which ones.
Has leflunomide been recalled?
4 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the leflunomide label last change?
The official label was last updated on December 19, 2025 (version 2). See what changed.
Talk about leflunomide
No comments yet. Questions, tips, what worked for you - start the conversation.